nodes	percent_of_prediction	percent_of_DWPC	metapath
Valproic Acid—CYP2C18—Ifosfamide—testicular cancer	0.109	0.157	CbGbCtD
Valproic Acid—UGT2B7—Epirubicin—testicular cancer	0.0633	0.091	CbGbCtD
Valproic Acid—SLC16A1—Methotrexate—testicular cancer	0.06	0.0862	CbGbCtD
Valproic Acid—SLC22A5—Dactinomycin—testicular cancer	0.0591	0.0848	CbGbCtD
Valproic Acid—CYP2A6—Ifosfamide—testicular cancer	0.053	0.0762	CbGbCtD
Valproic Acid—PTGS1—Ifosfamide—testicular cancer	0.0453	0.0651	CbGbCtD
Valproic Acid—CYP2B6—Ifosfamide—testicular cancer	0.0345	0.0496	CbGbCtD
Valproic Acid—SLC22A7—Methotrexate—testicular cancer	0.0295	0.0424	CbGbCtD
Valproic Acid—CYP3A5—Ifosfamide—testicular cancer	0.0272	0.0391	CbGbCtD
Valproic Acid—CYP2C8—Ifosfamide—testicular cancer	0.0262	0.0376	CbGbCtD
Valproic Acid—CYP2C19—Ifosfamide—testicular cancer	0.0219	0.0315	CbGbCtD
Valproic Acid—PTGS1—Etoposide—testicular cancer	0.0217	0.0311	CbGbCtD
Valproic Acid—CYP2C9—Ifosfamide—testicular cancer	0.0182	0.0262	CbGbCtD
Valproic Acid—SLC22A8—Methotrexate—testicular cancer	0.018	0.0259	CbGbCtD
Valproic Acid—CYP2B6—Cisplatin—testicular cancer	0.0168	0.0241	CbGbCtD
Valproic Acid—CYP3A5—Etoposide—testicular cancer	0.013	0.0187	CbGbCtD
Valproic Acid—SLC22A6—Methotrexate—testicular cancer	0.0125	0.018	CbGbCtD
Valproic Acid—CYP2C8—Etoposide—testicular cancer	0.0125	0.0179	CbGbCtD
Valproic Acid—CYP2B6—Doxorubicin—testicular cancer	0.0113	0.0162	CbGbCtD
Valproic Acid—CYP3A4—Ifosfamide—testicular cancer	0.0106	0.0152	CbGbCtD
Valproic Acid—CYP1A2—Etoposide—testicular cancer	0.00967	0.0139	CbGbCtD
Valproic Acid—CYP2C9—Cisplatin—testicular cancer	0.00887	0.0127	CbGbCtD
Valproic Acid—CYP3A4—Vinblastine—testicular cancer	0.00563	0.00808	CbGbCtD
Valproic Acid—CYP3A4—Etoposide—testicular cancer	0.00507	0.00728	CbGbCtD
Valproic Acid—CYP3A4—Doxorubicin—testicular cancer	0.00346	0.00496	CbGbCtD
Valproic Acid—ACADSB—seminal vesicle—testicular cancer	0.00298	0.0575	CbGeAlD
Valproic Acid—OGDH—gonad—testicular cancer	0.00271	0.0523	CbGeAlD
Valproic Acid—UGT1A6—testis—testicular cancer	0.00247	0.0477	CbGeAlD
Valproic Acid—HDAC2—Teniposide—Etoposide—testicular cancer	0.00227	1	CbGdCrCtD
Valproic Acid—OGDH—female gonad—testicular cancer	0.0022	0.0425	CbGeAlD
Valproic Acid—OGDH—testis—testicular cancer	0.00195	0.0377	CbGeAlD
Valproic Acid—HDAC9—female gonad—testicular cancer	0.00194	0.0374	CbGeAlD
Valproic Acid—ALDH5A1—gonad—testicular cancer	0.0019	0.0366	CbGeAlD
Valproic Acid—HDAC2—embryo—testicular cancer	0.0018	0.0347	CbGeAlD
Valproic Acid—ACADSB—female gonad—testicular cancer	0.00175	0.0337	CbGeAlD
Valproic Acid—HDAC9—testis—testicular cancer	0.00172	0.0332	CbGeAlD
Valproic Acid—ABAT—gonad—testicular cancer	0.00162	0.0313	CbGeAlD
Valproic Acid—ACADSB—testis—testicular cancer	0.00155	0.0299	CbGeAlD
Valproic Acid—ALDH5A1—female gonad—testicular cancer	0.00154	0.0297	CbGeAlD
Valproic Acid—CYP2A6—seminal vesicle—testicular cancer	0.00148	0.0285	CbGeAlD
Valproic Acid—OGDH—lymph node—testicular cancer	0.00142	0.0273	CbGeAlD
Valproic Acid—ALDH5A1—testis—testicular cancer	0.00137	0.0263	CbGeAlD
Valproic Acid—ABAT—female gonad—testicular cancer	0.00132	0.0254	CbGeAlD
Valproic Acid—HDAC9—lymph node—testicular cancer	0.00125	0.0241	CbGeAlD
Valproic Acid—HDAC2—gonad—testicular cancer	0.00122	0.0236	CbGeAlD
Valproic Acid—ABAT—testis—testicular cancer	0.00117	0.0225	CbGeAlD
Valproic Acid—ACADSB—lymph node—testicular cancer	0.00112	0.0217	CbGeAlD
Valproic Acid—SLC16A1—gonad—testicular cancer	0.00109	0.0209	CbGeAlD
Valproic Acid—UGT2B7—testis—testicular cancer	0.00108	0.0207	CbGeAlD
Valproic Acid—UGT1A6—NRF2 pathway—SLC2A6—testicular cancer	0.00107	0.0406	CbGpPWpGaD
Valproic Acid—SLC16A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00102	0.0388	CbGpPWpGaD
Valproic Acid—SLC22A7—testis—testicular cancer	0.00102	0.0197	CbGeAlD
Valproic Acid—HDAC2—female gonad—testicular cancer	0.000992	0.0191	CbGeAlD
Valproic Acid—ALDH5A1—lymph node—testicular cancer	0.00099	0.0191	CbGeAlD
Valproic Acid—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000947	0.0359	CbGpPWpGaD
Valproic Acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000918	0.0348	CbGpPWpGaD
Valproic Acid—SLC16A1—female gonad—testicular cancer	0.000882	0.017	CbGeAlD
Valproic Acid—HDAC2—testis—testicular cancer	0.00088	0.017	CbGeAlD
Valproic Acid—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00088	0.0333	CbGpPWpGaD
Valproic Acid—SLC22A5—seminal vesicle—testicular cancer	0.000858	0.0165	CbGeAlD
Valproic Acid—ABAT—lymph node—testicular cancer	0.000847	0.0163	CbGeAlD
Valproic Acid—UGT1A4—NRF2 pathway—SLC2A6—testicular cancer	0.000828	0.0314	CbGpPWpGaD
Valproic Acid—UGT1A8—Phase II conjugation—HPGDS—testicular cancer	0.0008	0.0303	CbGpPWpGaD
Valproic Acid—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000796	0.0301	CbGpPWpGaD
Valproic Acid—SLC16A1—testis—testicular cancer	0.000782	0.0151	CbGeAlD
Valproic Acid—UGT2B15—Phase II conjugation—HPGDS—testicular cancer	0.000699	0.0265	CbGpPWpGaD
Valproic Acid—UGT1A3—NRF2 pathway—SLC2A6—testicular cancer	0.000688	0.0261	CbGpPWpGaD
Valproic Acid—PTGS1—seminal vesicle—testicular cancer	0.000674	0.013	CbGeAlD
Valproic Acid—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000664	0.0252	CbGpPWpGaD
Valproic Acid—HDAC2—lymph node—testicular cancer	0.000638	0.0123	CbGeAlD
Valproic Acid—HDAC2—Epigenetic regulation of gene expression—DNMT3L—testicular cancer	0.000591	0.0224	CbGpPWpGaD
Valproic Acid—UGT2B7—NRF2 pathway—SLC2A6—testicular cancer	0.000585	0.0222	CbGpPWpGaD
Valproic Acid—UGT1A6—Phase II conjugation—HPGDS—testicular cancer	0.000584	0.0221	CbGpPWpGaD
Valproic Acid—SLC16A1—lymph node—testicular cancer	0.000567	0.0109	CbGeAlD
Valproic Acid—CYP2B6—gonad—testicular cancer	0.000538	0.0104	CbGeAlD
Valproic Acid—SLC22A5—female gonad—testicular cancer	0.000504	0.00972	CbGeAlD
Valproic Acid—UGT1A9—NRF2 pathway—SLC2A6—testicular cancer	0.000476	0.018	CbGpPWpGaD
Valproic Acid—UGT1A8—Biological oxidations—HPGDS—testicular cancer	0.000468	0.0177	CbGpPWpGaD
Valproic Acid—SLC16A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000465	0.0176	CbGpPWpGaD
Valproic Acid—UGT1A4—Phase II conjugation—HPGDS—testicular cancer	0.000451	0.0171	CbGpPWpGaD
Valproic Acid—SLC22A5—testis—testicular cancer	0.000447	0.00862	CbGeAlD
Valproic Acid—CYP3A5—female gonad—testicular cancer	0.00044	0.00849	CbGeAlD
Valproic Acid—CYP2C8—testis—testicular cancer	0.000433	0.00834	CbGeAlD
Valproic Acid—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00043	0.0163	CbGpPWpGaD
Valproic Acid—UGT2B15—Biological oxidations—HPGDS—testicular cancer	0.000409	0.0155	CbGpPWpGaD
Valproic Acid—SLC22A5—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0004	0.0151	CbGpPWpGaD
Valproic Acid—PTGS1—female gonad—testicular cancer	0.000396	0.00763	CbGeAlD
Valproic Acid—CYP2B6—testis—testicular cancer	0.000388	0.00749	CbGeAlD
Valproic Acid—HDAC9—Neural Crest Differentiation—FGFR3—testicular cancer	0.000379	0.0144	CbGpPWpGaD
Valproic Acid—UGT1A3—Phase II conjugation—HPGDS—testicular cancer	0.000375	0.0142	CbGpPWpGaD
Valproic Acid—CYP2A6—NRF2 pathway—SLC2A6—testicular cancer	0.000367	0.0139	CbGpPWpGaD
Valproic Acid—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000362	0.0137	CbGpPWpGaD
Valproic Acid—PTGS1—testis—testicular cancer	0.000351	0.00677	CbGeAlD
Valproic Acid—HDAC2—Cell Cycle—MAD1L1—testicular cancer	0.000342	0.013	CbGpPWpGaD
Valproic Acid—UGT1A6—Biological oxidations—HPGDS—testicular cancer	0.000341	0.0129	CbGpPWpGaD
Valproic Acid—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000332	0.0126	CbGpPWpGaD
Valproic Acid—SLC22A5—lymph node—testicular cancer	0.000324	0.00625	CbGeAlD
Valproic Acid—UGT2B7—Phase II conjugation—HPGDS—testicular cancer	0.000318	0.0121	CbGpPWpGaD
Valproic Acid—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000302	0.0114	CbGpPWpGaD
Valproic Acid—UGT1A4—Biological oxidations—HPGDS—testicular cancer	0.000264	0.00998	CbGpPWpGaD
Valproic Acid—UGT1A9—Phase II conjugation—HPGDS—testicular cancer	0.000259	0.0098	CbGpPWpGaD
Valproic Acid—PTGS1—lymph node—testicular cancer	0.000254	0.00491	CbGeAlD
Valproic Acid—HDAC2—NoRC negatively regulates rRNA expression—H2AFZ—testicular cancer	0.000238	0.00903	CbGpPWpGaD
Valproic Acid—SLC16A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000236	0.00895	CbGpPWpGaD
Valproic Acid—HDAC2—Negative epigenetic regulation of rRNA expression—H2AFZ—testicular cancer	0.000233	0.00883	CbGpPWpGaD
Valproic Acid—HDAC2—RNA Polymerase I Promoter Clearance—H2AFZ—testicular cancer	0.000233	0.00883	CbGpPWpGaD
Valproic Acid—HDAC2—RNA Polymerase I Transcription—H2AFZ—testicular cancer	0.00023	0.00869	CbGpPWpGaD
Valproic Acid—HDAC2—Cell Cycle—KITLG—testicular cancer	0.000219	0.00831	CbGpPWpGaD
Valproic Acid—UGT1A3—Biological oxidations—HPGDS—testicular cancer	0.000219	0.0083	CbGpPWpGaD
Valproic Acid—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000219	0.00828	CbGpPWpGaD
Valproic Acid—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000214	0.00811	CbGpPWpGaD
Valproic Acid—HDAC2—Epigenetic regulation of gene expression—H2AFZ—testicular cancer	0.000207	0.00783	CbGpPWpGaD
Valproic Acid—SLC22A5—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000203	0.0077	CbGpPWpGaD
Valproic Acid—CYP2C18—Biological oxidations—HPGDS—testicular cancer	0.000192	0.00725	CbGpPWpGaD
Valproic Acid—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000191	0.00724	CbGpPWpGaD
Valproic Acid—UGT2B7—Biological oxidations—HPGDS—testicular cancer	0.000186	0.00706	CbGpPWpGaD
Valproic Acid—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000184	0.00696	CbGpPWpGaD
Valproic Acid—HDAC2—RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription—H2AFZ—testicular cancer	0.000183	0.00693	CbGpPWpGaD
Valproic Acid—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000174	0.0066	CbGpPWpGaD
Valproic Acid—HDAC2—Neural Crest Differentiation—FGFR3—testicular cancer	0.000164	0.00622	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—INSL3—testicular cancer	0.000162	0.00613	CbGpPWpGaD
Valproic Acid—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.000161	0.0061	CbGpPWpGaD
Valproic Acid—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000159	0.00603	CbGpPWpGaD
Valproic Acid—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000153	0.00581	CbGpPWpGaD
Valproic Acid—ACADSB—Metabolism—HPGDS—testicular cancer	0.000152	0.00577	CbGpPWpGaD
Valproic Acid—UGT1A9—Biological oxidations—HPGDS—testicular cancer	0.000151	0.00573	CbGpPWpGaD
Valproic Acid—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000149	0.00564	CbGpPWpGaD
Valproic Acid—HDAC2—Chromatin modifying enzymes—H2AFZ—testicular cancer	0.00013	0.00494	CbGpPWpGaD
Valproic Acid—OGDH—Metabolism—HPGDS—testicular cancer	0.00013	0.00491	CbGpPWpGaD
Valproic Acid—HDAC2—Transcription—H2AFZ—testicular cancer	0.000124	0.0047	CbGpPWpGaD
Valproic Acid—PTGS1—Biological oxidations—HPGDS—testicular cancer	0.000123	0.00467	CbGpPWpGaD
Valproic Acid—CYP2A6—Biological oxidations—HPGDS—testicular cancer	0.000117	0.00442	CbGpPWpGaD
Valproic Acid—ACADSB—Metabolism—STK11—testicular cancer	0.000111	0.00419	CbGpPWpGaD
Valproic Acid—Dermatitis—Ifosfamide—testicular cancer	0.000105	0.000472	CcSEcCtD
Valproic Acid—Erythema multiforme—Methotrexate—testicular cancer	0.000105	0.000472	CcSEcCtD
Valproic Acid—Urticaria—Etoposide—testicular cancer	0.000105	0.000471	CcSEcCtD
Valproic Acid—Haemoglobin—Epirubicin—testicular cancer	0.000105	0.00047	CcSEcCtD
Valproic Acid—Stomatitis—Doxorubicin—testicular cancer	0.000105	0.00047	CcSEcCtD
Valproic Acid—Rhinitis—Epirubicin—testicular cancer	0.000105	0.000469	CcSEcCtD
Valproic Acid—Abdominal pain—Etoposide—testicular cancer	0.000104	0.000468	CcSEcCtD
Valproic Acid—Body temperature increased—Etoposide—testicular cancer	0.000104	0.000468	CcSEcCtD
Valproic Acid—Urinary tract infection—Doxorubicin—testicular cancer	0.000104	0.000468	CcSEcCtD
Valproic Acid—Conjunctivitis—Doxorubicin—testicular cancer	0.000104	0.000468	CcSEcCtD
Valproic Acid—Haemorrhage—Epirubicin—testicular cancer	0.000104	0.000467	CcSEcCtD
Valproic Acid—Eye disorder—Methotrexate—testicular cancer	0.000104	0.000467	CcSEcCtD
Valproic Acid—Tinnitus—Methotrexate—testicular cancer	0.000104	0.000466	CcSEcCtD
Valproic Acid—Hypoaesthesia—Epirubicin—testicular cancer	0.000104	0.000465	CcSEcCtD
Valproic Acid—Asthenia—Cisplatin—testicular cancer	0.000104	0.000464	CcSEcCtD
Valproic Acid—Pharyngitis—Epirubicin—testicular cancer	0.000104	0.000464	CcSEcCtD
Valproic Acid—Sweating—Doxorubicin—testicular cancer	0.000103	0.000462	CcSEcCtD
Valproic Acid—Urinary tract disorder—Epirubicin—testicular cancer	0.000103	0.000462	CcSEcCtD
Valproic Acid—HDAC2—Direct p53 effectors—MMP2—testicular cancer	0.000103	0.0039	CbGpPWpGaD
Valproic Acid—Oedema peripheral—Epirubicin—testicular cancer	0.000103	0.00046	CcSEcCtD
Valproic Acid—Connective tissue disorder—Epirubicin—testicular cancer	0.000102	0.000459	CcSEcCtD
Valproic Acid—Urethral disorder—Epirubicin—testicular cancer	0.000102	0.000458	CcSEcCtD
Valproic Acid—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000102	0.000456	CcSEcCtD
Valproic Acid—Epistaxis—Doxorubicin—testicular cancer	0.000101	0.000454	CcSEcCtD
Valproic Acid—Angiopathy—Methotrexate—testicular cancer	0.000101	0.000453	CcSEcCtD
Valproic Acid—Sinusitis—Doxorubicin—testicular cancer	0.000101	0.000452	CcSEcCtD
Valproic Acid—Immune system disorder—Methotrexate—testicular cancer	0.000101	0.000451	CcSEcCtD
Valproic Acid—Visual impairment—Epirubicin—testicular cancer	0.0001	0.00045	CcSEcCtD
Valproic Acid—Mediastinal disorder—Methotrexate—testicular cancer	0.0001	0.00045	CcSEcCtD
Valproic Acid—Agranulocytosis—Doxorubicin—testicular cancer	0.0001	0.00045	CcSEcCtD
Valproic Acid—Chills—Methotrexate—testicular cancer	0.0001	0.000448	CcSEcCtD
Valproic Acid—Nausea—Ifosfamide—testicular cancer	9.94e-05	0.000445	CcSEcCtD
Valproic Acid—Diarrhoea—Cisplatin—testicular cancer	9.87e-05	0.000442	CcSEcCtD
Valproic Acid—HDAC2—Gene Expression—DNMT3L—testicular cancer	9.87e-05	0.00374	CbGpPWpGaD
Valproic Acid—Erythema multiforme—Epirubicin—testicular cancer	9.86e-05	0.000442	CcSEcCtD
Valproic Acid—Alopecia—Methotrexate—testicular cancer	9.85e-05	0.000441	CcSEcCtD
Valproic Acid—Bradycardia—Doxorubicin—testicular cancer	9.82e-05	0.00044	CcSEcCtD
Valproic Acid—Mental disorder—Methotrexate—testicular cancer	9.76e-05	0.000438	CcSEcCtD
Valproic Acid—Eye disorder—Epirubicin—testicular cancer	9.75e-05	0.000437	CcSEcCtD
Valproic Acid—Hypersensitivity—Etoposide—testicular cancer	9.74e-05	0.000436	CcSEcCtD
Valproic Acid—Tinnitus—Epirubicin—testicular cancer	9.72e-05	0.000436	CcSEcCtD
Valproic Acid—Malnutrition—Methotrexate—testicular cancer	9.7e-05	0.000435	CcSEcCtD
Valproic Acid—Haemoglobin—Doxorubicin—testicular cancer	9.7e-05	0.000435	CcSEcCtD
Valproic Acid—Rhinitis—Doxorubicin—testicular cancer	9.67e-05	0.000434	CcSEcCtD
Valproic Acid—Haemorrhage—Doxorubicin—testicular cancer	9.65e-05	0.000432	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—KITLG—testicular cancer	9.62e-05	0.00364	CbGpPWpGaD
Valproic Acid—Hypoaesthesia—Doxorubicin—testicular cancer	9.6e-05	0.00043	CcSEcCtD
Valproic Acid—Pharyngitis—Doxorubicin—testicular cancer	9.58e-05	0.000429	CcSEcCtD
Valproic Acid—Urinary tract disorder—Doxorubicin—testicular cancer	9.53e-05	0.000427	CcSEcCtD
Valproic Acid—Oedema peripheral—Doxorubicin—testicular cancer	9.51e-05	0.000426	CcSEcCtD
Valproic Acid—Dysgeusia—Methotrexate—testicular cancer	9.5e-05	0.000426	CcSEcCtD
Valproic Acid—Asthenia—Etoposide—testicular cancer	9.48e-05	0.000425	CcSEcCtD
Valproic Acid—Connective tissue disorder—Doxorubicin—testicular cancer	9.48e-05	0.000425	CcSEcCtD
Valproic Acid—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	9.48e-05	0.00359	CbGpPWpGaD
Valproic Acid—Angiopathy—Epirubicin—testicular cancer	9.46e-05	0.000424	CcSEcCtD
Valproic Acid—Urethral disorder—Doxorubicin—testicular cancer	9.46e-05	0.000424	CcSEcCtD
Valproic Acid—Immune system disorder—Epirubicin—testicular cancer	9.42e-05	0.000422	CcSEcCtD
Valproic Acid—CYP2B6—Biological oxidations—HPGDS—testicular cancer	9.42e-05	0.00357	CbGpPWpGaD
Valproic Acid—OGDH—Metabolism—STK11—testicular cancer	9.41e-05	0.00356	CbGpPWpGaD
Valproic Acid—Mediastinal disorder—Epirubicin—testicular cancer	9.4e-05	0.000421	CcSEcCtD
Valproic Acid—Back pain—Methotrexate—testicular cancer	9.38e-05	0.00042	CcSEcCtD
Valproic Acid—Chills—Epirubicin—testicular cancer	9.36e-05	0.000419	CcSEcCtD
Valproic Acid—Pruritus—Etoposide—testicular cancer	9.35e-05	0.000419	CcSEcCtD
Valproic Acid—Arrhythmia—Epirubicin—testicular cancer	9.32e-05	0.000417	CcSEcCtD
Valproic Acid—Visual impairment—Doxorubicin—testicular cancer	9.3e-05	0.000417	CcSEcCtD
Valproic Acid—Alopecia—Epirubicin—testicular cancer	9.22e-05	0.000413	CcSEcCtD
Valproic Acid—CYP3A5—Biological oxidations—HPGDS—testicular cancer	9.2e-05	0.00349	CbGpPWpGaD
Valproic Acid—Vomiting—Cisplatin—testicular cancer	9.17e-05	0.000411	CcSEcCtD
Valproic Acid—Vision blurred—Methotrexate—testicular cancer	9.14e-05	0.00041	CcSEcCtD
Valproic Acid—Mental disorder—Epirubicin—testicular cancer	9.14e-05	0.000409	CcSEcCtD
Valproic Acid—Erythema multiforme—Doxorubicin—testicular cancer	9.12e-05	0.000409	CcSEcCtD
Valproic Acid—Rash—Cisplatin—testicular cancer	9.1e-05	0.000408	CcSEcCtD
Valproic Acid—Dermatitis—Cisplatin—testicular cancer	9.09e-05	0.000407	CcSEcCtD
Valproic Acid—Malnutrition—Epirubicin—testicular cancer	9.08e-05	0.000407	CcSEcCtD
Valproic Acid—Diarrhoea—Etoposide—testicular cancer	9.04e-05	0.000405	CcSEcCtD
Valproic Acid—Eye disorder—Doxorubicin—testicular cancer	9.02e-05	0.000404	CcSEcCtD
Valproic Acid—Ill-defined disorder—Methotrexate—testicular cancer	9e-05	0.000403	CcSEcCtD
Valproic Acid—Tinnitus—Doxorubicin—testicular cancer	9e-05	0.000403	CcSEcCtD
Valproic Acid—Anaemia—Methotrexate—testicular cancer	8.97e-05	0.000402	CcSEcCtD
Valproic Acid—Flatulence—Epirubicin—testicular cancer	8.95e-05	0.000401	CcSEcCtD
Valproic Acid—Tension—Epirubicin—testicular cancer	8.91e-05	0.000399	CcSEcCtD
Valproic Acid—Dysgeusia—Epirubicin—testicular cancer	8.89e-05	0.000398	CcSEcCtD
Valproic Acid—Nervousness—Epirubicin—testicular cancer	8.82e-05	0.000395	CcSEcCtD
Valproic Acid—Back pain—Epirubicin—testicular cancer	8.78e-05	0.000394	CcSEcCtD
Valproic Acid—Angiopathy—Doxorubicin—testicular cancer	8.75e-05	0.000392	CcSEcCtD
Valproic Acid—Malaise—Methotrexate—testicular cancer	8.75e-05	0.000392	CcSEcCtD
Valproic Acid—Dizziness—Etoposide—testicular cancer	8.74e-05	0.000392	CcSEcCtD
Valproic Acid—Muscle spasms—Epirubicin—testicular cancer	8.73e-05	0.000391	CcSEcCtD
Valproic Acid—Immune system disorder—Doxorubicin—testicular cancer	8.72e-05	0.000391	CcSEcCtD
Valproic Acid—Vertigo—Methotrexate—testicular cancer	8.72e-05	0.000391	CcSEcCtD
Valproic Acid—Mediastinal disorder—Doxorubicin—testicular cancer	8.7e-05	0.00039	CcSEcCtD
Valproic Acid—Leukopenia—Methotrexate—testicular cancer	8.68e-05	0.000389	CcSEcCtD
Valproic Acid—Chills—Doxorubicin—testicular cancer	8.66e-05	0.000388	CcSEcCtD
Valproic Acid—Arrhythmia—Doxorubicin—testicular cancer	8.62e-05	0.000386	CcSEcCtD
Valproic Acid—Nausea—Cisplatin—testicular cancer	8.57e-05	0.000384	CcSEcCtD
Valproic Acid—Vision blurred—Epirubicin—testicular cancer	8.56e-05	0.000383	CcSEcCtD
Valproic Acid—Alopecia—Doxorubicin—testicular cancer	8.53e-05	0.000382	CcSEcCtD
Valproic Acid—Cough—Methotrexate—testicular cancer	8.47e-05	0.000379	CcSEcCtD
Valproic Acid—Mental disorder—Doxorubicin—testicular cancer	8.45e-05	0.000379	CcSEcCtD
Valproic Acid—Ill-defined disorder—Epirubicin—testicular cancer	8.42e-05	0.000377	CcSEcCtD
Valproic Acid—Vomiting—Etoposide—testicular cancer	8.4e-05	0.000377	CcSEcCtD
Valproic Acid—Malnutrition—Doxorubicin—testicular cancer	8.4e-05	0.000376	CcSEcCtD
Valproic Acid—Anaemia—Epirubicin—testicular cancer	8.39e-05	0.000376	CcSEcCtD
Valproic Acid—Agitation—Epirubicin—testicular cancer	8.34e-05	0.000374	CcSEcCtD
Valproic Acid—Rash—Etoposide—testicular cancer	8.33e-05	0.000373	CcSEcCtD
Valproic Acid—Dermatitis—Etoposide—testicular cancer	8.33e-05	0.000373	CcSEcCtD
Valproic Acid—Headache—Etoposide—testicular cancer	8.28e-05	0.000371	CcSEcCtD
Valproic Acid—Flatulence—Doxorubicin—testicular cancer	8.28e-05	0.000371	CcSEcCtD
Valproic Acid—Myalgia—Methotrexate—testicular cancer	8.26e-05	0.00037	CcSEcCtD
Valproic Acid—Arthralgia—Methotrexate—testicular cancer	8.26e-05	0.00037	CcSEcCtD
Valproic Acid—Chest pain—Methotrexate—testicular cancer	8.26e-05	0.00037	CcSEcCtD
Valproic Acid—Tension—Doxorubicin—testicular cancer	8.24e-05	0.000369	CcSEcCtD
Valproic Acid—Dysgeusia—Doxorubicin—testicular cancer	8.23e-05	0.000369	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	8.2e-05	0.000368	CcSEcCtD
Valproic Acid—Malaise—Epirubicin—testicular cancer	8.19e-05	0.000367	CcSEcCtD
Valproic Acid—Discomfort—Methotrexate—testicular cancer	8.16e-05	0.000366	CcSEcCtD
Valproic Acid—Nervousness—Doxorubicin—testicular cancer	8.16e-05	0.000366	CcSEcCtD
Valproic Acid—Vertigo—Epirubicin—testicular cancer	8.16e-05	0.000366	CcSEcCtD
Valproic Acid—Leukopenia—Epirubicin—testicular cancer	8.13e-05	0.000364	CcSEcCtD
Valproic Acid—Back pain—Doxorubicin—testicular cancer	8.13e-05	0.000364	CcSEcCtD
Valproic Acid—Muscle spasms—Doxorubicin—testicular cancer	8.08e-05	0.000362	CcSEcCtD
Valproic Acid—Palpitations—Epirubicin—testicular cancer	8.02e-05	0.00036	CcSEcCtD
Valproic Acid—UGT1A8—Metabolism—HPGDS—testicular cancer	8e-05	0.00303	CbGpPWpGaD
Valproic Acid—Confusional state—Methotrexate—testicular cancer	7.98e-05	0.000358	CcSEcCtD
Valproic Acid—CYP2C8—Biological oxidations—HPGDS—testicular cancer	7.97e-05	0.00302	CbGpPWpGaD
Valproic Acid—Cough—Epirubicin—testicular cancer	7.92e-05	0.000355	CcSEcCtD
Valproic Acid—Anaphylactic shock—Methotrexate—testicular cancer	7.92e-05	0.000355	CcSEcCtD
Valproic Acid—Vision blurred—Doxorubicin—testicular cancer	7.92e-05	0.000355	CcSEcCtD
Valproic Acid—Infection—Methotrexate—testicular cancer	7.87e-05	0.000352	CcSEcCtD
Valproic Acid—Nausea—Etoposide—testicular cancer	7.85e-05	0.000352	CcSEcCtD
Valproic Acid—Hypertension—Epirubicin—testicular cancer	7.84e-05	0.000351	CcSEcCtD
Valproic Acid—Ill-defined disorder—Doxorubicin—testicular cancer	7.79e-05	0.000349	CcSEcCtD
Valproic Acid—Nervous system disorder—Methotrexate—testicular cancer	7.76e-05	0.000348	CcSEcCtD
Valproic Acid—Anaemia—Doxorubicin—testicular cancer	7.76e-05	0.000348	CcSEcCtD
Valproic Acid—Thrombocytopenia—Methotrexate—testicular cancer	7.75e-05	0.000347	CcSEcCtD
Valproic Acid—Myalgia—Epirubicin—testicular cancer	7.73e-05	0.000346	CcSEcCtD
Valproic Acid—Chest pain—Epirubicin—testicular cancer	7.73e-05	0.000346	CcSEcCtD
Valproic Acid—Arthralgia—Epirubicin—testicular cancer	7.73e-05	0.000346	CcSEcCtD
Valproic Acid—Agitation—Doxorubicin—testicular cancer	7.72e-05	0.000346	CcSEcCtD
Valproic Acid—Anxiety—Epirubicin—testicular cancer	7.7e-05	0.000345	CcSEcCtD
Valproic Acid—Skin disorder—Methotrexate—testicular cancer	7.69e-05	0.000345	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	7.68e-05	0.000344	CcSEcCtD
Valproic Acid—Hyperhidrosis—Methotrexate—testicular cancer	7.65e-05	0.000343	CcSEcCtD
Valproic Acid—Discomfort—Epirubicin—testicular cancer	7.64e-05	0.000342	CcSEcCtD
Valproic Acid—Malaise—Doxorubicin—testicular cancer	7.57e-05	0.000339	CcSEcCtD
Valproic Acid—Dry mouth—Epirubicin—testicular cancer	7.56e-05	0.000339	CcSEcCtD
Valproic Acid—Vertigo—Doxorubicin—testicular cancer	7.55e-05	0.000338	CcSEcCtD
Valproic Acid—Anorexia—Methotrexate—testicular cancer	7.55e-05	0.000338	CcSEcCtD
Valproic Acid—Leukopenia—Doxorubicin—testicular cancer	7.52e-05	0.000337	CcSEcCtD
Valproic Acid—Confusional state—Epirubicin—testicular cancer	7.47e-05	0.000335	CcSEcCtD
Valproic Acid—Palpitations—Doxorubicin—testicular cancer	7.42e-05	0.000333	CcSEcCtD
Valproic Acid—Oedema—Epirubicin—testicular cancer	7.41e-05	0.000332	CcSEcCtD
Valproic Acid—Anaphylactic shock—Epirubicin—testicular cancer	7.41e-05	0.000332	CcSEcCtD
Valproic Acid—Hypotension—Methotrexate—testicular cancer	7.4e-05	0.000332	CcSEcCtD
Valproic Acid—HDAC9—Disease—H2AFZ—testicular cancer	7.39e-05	0.0028	CbGpPWpGaD
Valproic Acid—Infection—Epirubicin—testicular cancer	7.36e-05	0.00033	CcSEcCtD
Valproic Acid—Cough—Doxorubicin—testicular cancer	7.33e-05	0.000328	CcSEcCtD
Valproic Acid—Nervous system disorder—Epirubicin—testicular cancer	7.27e-05	0.000326	CcSEcCtD
Valproic Acid—Thrombocytopenia—Epirubicin—testicular cancer	7.25e-05	0.000325	CcSEcCtD
Valproic Acid—Hypertension—Doxorubicin—testicular cancer	7.25e-05	0.000325	CcSEcCtD
Valproic Acid—Tachycardia—Epirubicin—testicular cancer	7.23e-05	0.000324	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Methotrexate—testicular cancer	7.21e-05	0.000323	CcSEcCtD
Valproic Acid—Skin disorder—Epirubicin—testicular cancer	7.2e-05	0.000322	CcSEcCtD
Valproic Acid—Hyperhidrosis—Epirubicin—testicular cancer	7.16e-05	0.000321	CcSEcCtD
Valproic Acid—Insomnia—Methotrexate—testicular cancer	7.16e-05	0.000321	CcSEcCtD
Valproic Acid—Arthralgia—Doxorubicin—testicular cancer	7.15e-05	0.00032	CcSEcCtD
Valproic Acid—Chest pain—Doxorubicin—testicular cancer	7.15e-05	0.00032	CcSEcCtD
Valproic Acid—Myalgia—Doxorubicin—testicular cancer	7.15e-05	0.00032	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—FGFR3—testicular cancer	7.15e-05	0.00271	CbGpPWpGaD
Valproic Acid—Anxiety—Doxorubicin—testicular cancer	7.13e-05	0.000319	CcSEcCtD
Valproic Acid—CYP2C19—Biological oxidations—HPGDS—testicular cancer	7.11e-05	0.00269	CbGpPWpGaD
Valproic Acid—Paraesthesia—Methotrexate—testicular cancer	7.11e-05	0.000319	CcSEcCtD
Valproic Acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	7.1e-05	0.000318	CcSEcCtD
Valproic Acid—Discomfort—Doxorubicin—testicular cancer	7.07e-05	0.000317	CcSEcCtD
Valproic Acid—Anorexia—Epirubicin—testicular cancer	7.06e-05	0.000316	CcSEcCtD
Valproic Acid—Dyspnoea—Methotrexate—testicular cancer	7.06e-05	0.000316	CcSEcCtD
Valproic Acid—Somnolence—Methotrexate—testicular cancer	7.04e-05	0.000315	CcSEcCtD
Valproic Acid—HDAC2—Signaling Pathways—INSL3—testicular cancer	7.01e-05	0.00266	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—HPGDS—testicular cancer	6.99e-05	0.00265	CbGpPWpGaD
Valproic Acid—Dry mouth—Doxorubicin—testicular cancer	6.99e-05	0.000313	CcSEcCtD
Valproic Acid—Dyspepsia—Methotrexate—testicular cancer	6.97e-05	0.000312	CcSEcCtD
Valproic Acid—Hypotension—Epirubicin—testicular cancer	6.92e-05	0.00031	CcSEcCtD
Valproic Acid—Confusional state—Doxorubicin—testicular cancer	6.91e-05	0.00031	CcSEcCtD
Valproic Acid—Decreased appetite—Methotrexate—testicular cancer	6.88e-05	0.000308	CcSEcCtD
Valproic Acid—Oedema—Doxorubicin—testicular cancer	6.86e-05	0.000307	CcSEcCtD
Valproic Acid—Anaphylactic shock—Doxorubicin—testicular cancer	6.86e-05	0.000307	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Methotrexate—testicular cancer	6.84e-05	0.000306	CcSEcCtD
Valproic Acid—Fatigue—Methotrexate—testicular cancer	6.83e-05	0.000306	CcSEcCtD
Valproic Acid—Infection—Doxorubicin—testicular cancer	6.81e-05	0.000305	CcSEcCtD
Valproic Acid—HDAC9—Disease—KITLG—testicular cancer	6.8e-05	0.00258	CbGpPWpGaD
Valproic Acid—Pain—Methotrexate—testicular cancer	6.77e-05	0.000303	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Epirubicin—testicular cancer	6.75e-05	0.000302	CcSEcCtD
Valproic Acid—Nervous system disorder—Doxorubicin—testicular cancer	6.72e-05	0.000301	CcSEcCtD
Valproic Acid—Thrombocytopenia—Doxorubicin—testicular cancer	6.71e-05	0.000301	CcSEcCtD
Valproic Acid—Insomnia—Epirubicin—testicular cancer	6.7e-05	0.0003	CcSEcCtD
Valproic Acid—Tachycardia—Doxorubicin—testicular cancer	6.69e-05	0.0003	CcSEcCtD
Valproic Acid—Skin disorder—Doxorubicin—testicular cancer	6.66e-05	0.000298	CcSEcCtD
Valproic Acid—Paraesthesia—Epirubicin—testicular cancer	6.65e-05	0.000298	CcSEcCtD
Valproic Acid—Hyperhidrosis—Doxorubicin—testicular cancer	6.63e-05	0.000297	CcSEcCtD
Valproic Acid—Dyspnoea—Epirubicin—testicular cancer	6.61e-05	0.000296	CcSEcCtD
Valproic Acid—Somnolence—Epirubicin—testicular cancer	6.59e-05	0.000295	CcSEcCtD
Valproic Acid—HDAC2—Signaling by NGF—KIT—testicular cancer	6.56e-05	0.00249	CbGpPWpGaD
Valproic Acid—Anorexia—Doxorubicin—testicular cancer	6.53e-05	0.000293	CcSEcCtD
Valproic Acid—Feeling abnormal—Methotrexate—testicular cancer	6.52e-05	0.000292	CcSEcCtD
Valproic Acid—Dyspepsia—Epirubicin—testicular cancer	6.52e-05	0.000292	CcSEcCtD
Valproic Acid—CYP2C9—Biological oxidations—HPGDS—testicular cancer	6.49e-05	0.00246	CbGpPWpGaD
Valproic Acid—Gastrointestinal pain—Methotrexate—testicular cancer	6.47e-05	0.00029	CcSEcCtD
Valproic Acid—Decreased appetite—Epirubicin—testicular cancer	6.44e-05	0.000289	CcSEcCtD
Valproic Acid—Hypotension—Doxorubicin—testicular cancer	6.41e-05	0.000287	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Epirubicin—testicular cancer	6.4e-05	0.000287	CcSEcCtD
Valproic Acid—Fatigue—Epirubicin—testicular cancer	6.39e-05	0.000286	CcSEcCtD
Valproic Acid—Constipation—Epirubicin—testicular cancer	6.34e-05	0.000284	CcSEcCtD
Valproic Acid—Pain—Epirubicin—testicular cancer	6.34e-05	0.000284	CcSEcCtD
Valproic Acid—Urticaria—Methotrexate—testicular cancer	6.29e-05	0.000282	CcSEcCtD
Valproic Acid—Abdominal pain—Methotrexate—testicular cancer	6.26e-05	0.00028	CcSEcCtD
Valproic Acid—Body temperature increased—Methotrexate—testicular cancer	6.26e-05	0.00028	CcSEcCtD
Valproic Acid—Musculoskeletal discomfort—Doxorubicin—testicular cancer	6.25e-05	0.00028	CcSEcCtD
Valproic Acid—Insomnia—Doxorubicin—testicular cancer	6.2e-05	0.000278	CcSEcCtD
Valproic Acid—Paraesthesia—Doxorubicin—testicular cancer	6.16e-05	0.000276	CcSEcCtD
Valproic Acid—Dyspnoea—Doxorubicin—testicular cancer	6.11e-05	0.000274	CcSEcCtD
Valproic Acid—Feeling abnormal—Epirubicin—testicular cancer	6.11e-05	0.000274	CcSEcCtD
Valproic Acid—Somnolence—Doxorubicin—testicular cancer	6.09e-05	0.000273	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Epirubicin—testicular cancer	6.06e-05	0.000272	CcSEcCtD
Valproic Acid—Dyspepsia—Doxorubicin—testicular cancer	6.03e-05	0.00027	CcSEcCtD
Valproic Acid—Decreased appetite—Doxorubicin—testicular cancer	5.96e-05	0.000267	CcSEcCtD
Valproic Acid—Gastrointestinal disorder—Doxorubicin—testicular cancer	5.92e-05	0.000265	CcSEcCtD
Valproic Acid—Fatigue—Doxorubicin—testicular cancer	5.91e-05	0.000265	CcSEcCtD
Valproic Acid—Urticaria—Epirubicin—testicular cancer	5.89e-05	0.000264	CcSEcCtD
Valproic Acid—Constipation—Doxorubicin—testicular cancer	5.86e-05	0.000263	CcSEcCtD
Valproic Acid—Pain—Doxorubicin—testicular cancer	5.86e-05	0.000263	CcSEcCtD
Valproic Acid—Abdominal pain—Epirubicin—testicular cancer	5.86e-05	0.000262	CcSEcCtD
Valproic Acid—Body temperature increased—Epirubicin—testicular cancer	5.86e-05	0.000262	CcSEcCtD
Valproic Acid—UGT1A6—Metabolism—HPGDS—testicular cancer	5.84e-05	0.00221	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Methotrexate—testicular cancer	5.83e-05	0.000261	CcSEcCtD
Valproic Acid—UGT1A8—Metabolism—STK11—testicular cancer	5.81e-05	0.0022	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.81e-05	0.0022	CbGpPWpGaD
Valproic Acid—Asthenia—Methotrexate—testicular cancer	5.68e-05	0.000255	CcSEcCtD
Valproic Acid—Feeling abnormal—Doxorubicin—testicular cancer	5.65e-05	0.000253	CcSEcCtD
Valproic Acid—Gastrointestinal pain—Doxorubicin—testicular cancer	5.61e-05	0.000251	CcSEcCtD
Valproic Acid—Pruritus—Methotrexate—testicular cancer	5.6e-05	0.000251	CcSEcCtD
Valproic Acid—CYP1A2—Biological oxidations—HPGDS—testicular cancer	5.54e-05	0.0021	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Epirubicin—testicular cancer	5.46e-05	0.000245	CcSEcCtD
Valproic Acid—Urticaria—Doxorubicin—testicular cancer	5.45e-05	0.000244	CcSEcCtD
Valproic Acid—Body temperature increased—Doxorubicin—testicular cancer	5.42e-05	0.000243	CcSEcCtD
Valproic Acid—Abdominal pain—Doxorubicin—testicular cancer	5.42e-05	0.000243	CcSEcCtD
Valproic Acid—Diarrhoea—Methotrexate—testicular cancer	5.42e-05	0.000243	CcSEcCtD
Valproic Acid—Asthenia—Epirubicin—testicular cancer	5.32e-05	0.000238	CcSEcCtD
Valproic Acid—Pruritus—Epirubicin—testicular cancer	5.24e-05	0.000235	CcSEcCtD
Valproic Acid—Dizziness—Methotrexate—testicular cancer	5.24e-05	0.000235	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—H2AFZ—testicular cancer	5.18e-05	0.00196	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—STK11—testicular cancer	5.15e-05	0.00195	CbGpPWpGaD
Valproic Acid—UGT2B15—Metabolism—STK11—testicular cancer	5.08e-05	0.00192	CbGpPWpGaD
Valproic Acid—Diarrhoea—Epirubicin—testicular cancer	5.07e-05	0.000227	CcSEcCtD
Valproic Acid—HDAC9—Disease—FGFR3—testicular cancer	5.06e-05	0.00191	CbGpPWpGaD
Valproic Acid—Hypersensitivity—Doxorubicin—testicular cancer	5.05e-05	0.000226	CcSEcCtD
Valproic Acid—Vomiting—Methotrexate—testicular cancer	5.03e-05	0.000226	CcSEcCtD
Valproic Acid—Rash—Methotrexate—testicular cancer	4.99e-05	0.000224	CcSEcCtD
Valproic Acid—Dermatitis—Methotrexate—testicular cancer	4.99e-05	0.000223	CcSEcCtD
Valproic Acid—Headache—Methotrexate—testicular cancer	4.96e-05	0.000222	CcSEcCtD
Valproic Acid—Asthenia—Doxorubicin—testicular cancer	4.92e-05	0.00022	CcSEcCtD
Valproic Acid—Dizziness—Epirubicin—testicular cancer	4.9e-05	0.00022	CcSEcCtD
Valproic Acid—Pruritus—Doxorubicin—testicular cancer	4.85e-05	0.000217	CcSEcCtD
Valproic Acid—HDAC9—Signaling Pathways—KITLG—testicular cancer	4.76e-05	0.0018	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.74e-05	0.00179	CbGpPWpGaD
Valproic Acid—Vomiting—Epirubicin—testicular cancer	4.71e-05	0.000211	CcSEcCtD
Valproic Acid—Nausea—Methotrexate—testicular cancer	4.7e-05	0.000211	CcSEcCtD
Valproic Acid—Diarrhoea—Doxorubicin—testicular cancer	4.69e-05	0.00021	CcSEcCtD
Valproic Acid—Rash—Epirubicin—testicular cancer	4.67e-05	0.000209	CcSEcCtD
Valproic Acid—Dermatitis—Epirubicin—testicular cancer	4.67e-05	0.000209	CcSEcCtD
Valproic Acid—HDAC9—Disease—KIT—testicular cancer	4.64e-05	0.00176	CbGpPWpGaD
Valproic Acid—Headache—Epirubicin—testicular cancer	4.64e-05	0.000208	CcSEcCtD
Valproic Acid—Dizziness—Doxorubicin—testicular cancer	4.53e-05	0.000203	CcSEcCtD
Valproic Acid—UGT1A4—Metabolism—HPGDS—testicular cancer	4.51e-05	0.00171	CbGpPWpGaD
Valproic Acid—Nausea—Epirubicin—testicular cancer	4.4e-05	0.000197	CcSEcCtD
Valproic Acid—Vomiting—Doxorubicin—testicular cancer	4.36e-05	0.000195	CcSEcCtD
Valproic Acid—Rash—Doxorubicin—testicular cancer	4.32e-05	0.000194	CcSEcCtD
Valproic Acid—Dermatitis—Doxorubicin—testicular cancer	4.32e-05	0.000194	CcSEcCtD
Valproic Acid—Headache—Doxorubicin—testicular cancer	4.29e-05	0.000192	CcSEcCtD
Valproic Acid—CYP3A4—Biological oxidations—HPGDS—testicular cancer	4.28e-05	0.00162	CbGpPWpGaD
Valproic Acid—UGT1A6—Metabolism—STK11—testicular cancer	4.24e-05	0.00161	CbGpPWpGaD
Valproic Acid—Nausea—Doxorubicin—testicular cancer	4.07e-05	0.000182	CcSEcCtD
Valproic Acid—SLC16A1—Metabolism—HPGDS—testicular cancer	4.02e-05	0.00152	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—HPGDS—testicular cancer	3.75e-05	0.00142	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—FGFR3—testicular cancer	3.54e-05	0.00134	CbGpPWpGaD
Valproic Acid—HDAC2—Gene Expression—H2AFZ—testicular cancer	3.45e-05	0.00131	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—HPGDS—testicular cancer	3.28e-05	0.00124	CbGpPWpGaD
Valproic Acid—UGT1A4—Metabolism—STK11—testicular cancer	3.28e-05	0.00124	CbGpPWpGaD
Valproic Acid—HDAC9—Signaling Pathways—KIT—testicular cancer	3.25e-05	0.00123	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—H2AFZ—testicular cancer	3.21e-05	0.00121	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—HPGDS—testicular cancer	3.19e-05	0.00121	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.06e-05	0.00116	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—KITLG—testicular cancer	2.95e-05	0.00112	CbGpPWpGaD
Valproic Acid—SLC16A1—Metabolism—STK11—testicular cancer	2.92e-05	0.00111	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.73e-05	0.00103	CbGpPWpGaD
Valproic Acid—UGT1A3—Metabolism—STK11—testicular cancer	2.72e-05	0.00103	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—HPGDS—testicular cancer	2.59e-05	0.00098	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.49e-05	0.000943	CbGpPWpGaD
Valproic Acid—CYP2C18—Metabolism—STK11—testicular cancer	2.38e-05	0.000901	CbGpPWpGaD
Valproic Acid—UGT2B7—Metabolism—STK11—testicular cancer	2.31e-05	0.000877	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—H2AFZ—testicular cancer	2.25e-05	0.00085	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—STK11—testicular cancer	2.23e-05	0.000845	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—FGFR3—testicular cancer	2.19e-05	0.00083	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.13e-05	0.000806	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—HPGDS—testicular cancer	2.11e-05	0.000799	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—KITLG—testicular cancer	2.07e-05	0.000782	CbGpPWpGaD
Valproic Acid—HDAC2—Disease—KIT—testicular cancer	2.01e-05	0.000762	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—HPGDS—testicular cancer	2e-05	0.000756	CbGpPWpGaD
Valproic Acid—UGT1A9—Metabolism—STK11—testicular cancer	1.88e-05	0.000712	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—HPGDS—testicular cancer	1.61e-05	0.00061	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—HPGDS—testicular cancer	1.57e-05	0.000596	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—FGFR3—testicular cancer	1.54e-05	0.000581	CbGpPWpGaD
Valproic Acid—PTGS1—Metabolism—STK11—testicular cancer	1.53e-05	0.000581	CbGpPWpGaD
Valproic Acid—CYP2A6—Metabolism—STK11—testicular cancer	1.45e-05	0.000549	CbGpPWpGaD
Valproic Acid—HDAC2—Signaling Pathways—KIT—testicular cancer	1.41e-05	0.000534	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—HPGDS—testicular cancer	1.36e-05	0.000516	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—HPGDS—testicular cancer	1.22e-05	0.000461	CbGpPWpGaD
Valproic Acid—CYP2B6—Metabolism—STK11—testicular cancer	1.17e-05	0.000443	CbGpPWpGaD
Valproic Acid—CYP3A5—Metabolism—STK11—testicular cancer	1.14e-05	0.000433	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—HPGDS—testicular cancer	1.11e-05	0.00042	CbGpPWpGaD
Valproic Acid—CYP2C8—Metabolism—STK11—testicular cancer	9.9e-06	0.000375	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—HPGDS—testicular cancer	9.48e-06	0.000359	CbGpPWpGaD
Valproic Acid—CYP2C19—Metabolism—STK11—testicular cancer	8.84e-06	0.000335	CbGpPWpGaD
Valproic Acid—CYP2C9—Metabolism—STK11—testicular cancer	8.06e-06	0.000305	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—HPGDS—testicular cancer	7.32e-06	0.000277	CbGpPWpGaD
Valproic Acid—CYP1A2—Metabolism—STK11—testicular cancer	6.89e-06	0.000261	CbGpPWpGaD
Valproic Acid—CYP3A4—Metabolism—STK11—testicular cancer	5.32e-06	0.000201	CbGpPWpGaD
